Tiger Global Management Reduces $56M in Novo Nordisk A/S ($NVO)
Key Points
- Tiger Global Management changed its Novo Nordisk A/S ($NVO) stake by 100.0% last quarter, cutting to 0 shares.
- Wall Street's consensus rating on $NVO is Buy and an average price target of $47.29.
- $NVO last traded around $43.88.
Tiger Global Management reduced its position in Novo Nordisk A/S ($NVO), according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 0 shares of Novo Nordisk A/S after selling 1,269,000 shares during the quarter.
Novo Nordisk A/S ($NVO) Stock
Novo Nordisk A/S Earnings
Novo Nordisk A/S Dividend
Analysts Set New Price Targets
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.